Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis
Authors' conclusion
In this retrospective cohort of adults with SCD and osteoporosis on alendronate for a median of 48 months, we found no significant interactions between sex and changes in lumbar spine, femoral neck, or total hip BMD with alendronate.
Study context
- Population
- Adults with sickle cell disease (SCD) and osteoporosis treated with alendronate at a single centre in Brazil (2009–2019)69% females, 73% HbSS
- Participants
- 64 adults
- Exposure
- Females vs Males
- Outcome
- BMD changes (DXA of lumbar spine, femoral neck and total hip) by alendronate treatment duration, stratified by sex, skeletal site and SCD genotype
Methodological detailssingle-centre, Alendronate for a median (IQR) of 48 (29, 73) months
- Single-centre
- Alendronate for a median (IQR) of 48 (29, 73) months
Main finding
As reported in the abstract
BMD changes with alendronate
Mean lumbar spine bone mineral density (BMD) change in those on alendronate >5 years (g/cm²)
0.0357
p = 0.028
Observational data: associations, not effects.
Further findings
Baseline femoral neck BMD (g/cm²)
P = < 0.001
Baseline total hip BMD (g/cm²)
P = 0.009
Safety
Mild therapy-related side effects
- Adults reporting mild therapy-related side effects
- 4 (6.3%)
Atypical femoral diaphysis fracture attributed to alendronate
- Incidentally noted in a 37-year-old man on treatment for 4 years
- 1
Original publication
Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis. Osteoporos Int. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →